[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335283-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335283-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-performance-status-albumin-and-crp-in-last-line-chemotherapy-for-pancreatic-vs-other-gastrointestinal-cancerssimple-tools-matter","Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers—Simple Tools Matter","","Patients with advanced gastrointestinal cancers often receive chemotherapy near the end of life (EoL), raising concerns about overtreatment. The PALLiON trial, a cluster-randomized study, examined effects of a complex intervention involving palliative care referrals and PROMs. This secondary analysis evaluated how baseline performance status (PS), albumin (alb), C-reactive protein (CRP), and BMI relate to overall survival, comparing pancreatic (PAN) with other gastrointestinal (GI) cancers. PS ≤2 and alb \u003C35 g/L consistently predicted shorter survival. CRP >10 predicted shorter survival only in GI cancers, while BMI did not improve prediction models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-performance-status-albumin-and-crp-in-last-line-chemotherapy-for-pancreatic-vs-other-gastrointestinal-cancerssimple-tools-matter/335283/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-performance-status-albumin-and-crp-in-last-line-chemotherapy-for-pancreatic-vs-other-gastrointestinal-cancerssimple-tools-matter/335283.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What baseline factors were assessed for prognosis in last-line chemotherapy patients?","Question",{"text":63,"@type":64},"Baseline performance status (PS), albumin (alb), C-reactive protein (CRP), and body mass index (BMI) were evaluated for overall survival, alongside the modified Glasgow prognostic score (mGPS).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did PS and albumin relate to survival in pancreatic versus other gastrointestinal cancers?",{"text":68,"@type":64},"PS ≤2 and albumin \u003C35 g/L predicted shorter survival in both pancreatic and other gastrointestinal cancers after adjustment for age, sex, and hospital size.",{"name":70,"@type":61,"acceptedAnswer":71},"Did BMI improve prognostic prediction models?",{"text":72,"@type":64},"No. BMI did not improve predictive models, whereas PS and albumin (and increased CRP with low albumin for mGPS ≤2 in GI) were more informative.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335283,1790136669,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nPrognostic Value of Performance Status, Albumin, and CRPin Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers—Simple Tools Matter  \nArne Westgaard 1,2, *, Aleksandra Pirnat 1,2, Marianne Jensen Hjermstad 1,2, Nina Aass 1,2, Stein Kaasa 1,2,† and Olav Faisal Dajani 1,2,†  \nCitation: Westgaard, A.; Pirnat, A.; Hjermstad, M.J.; Aass, N.; Kaasa, S.; Dajani, O.F. Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers—Simple Tools Matter. Curr. Oncol. 2024, 31, 5462–5471. [https://](https://)[ ](https://)[doi.org/10.3390/curroncol31090404](doi.org/10.3390/curroncol31090404)  \nReceived: 13 August 2024  \nRevised: 10 September 2024  \nAccepted: 12 September 2024  \nPublished: 14 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway; [n.k.aass@medisin.uio.no](n.k.aass@medisin.uio.no) (N.A.); [uxolaj@ous-hf.no](uxolaj@ous-hf.no) (O.F.D.)  \n2 European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway  \n* Correspondence: [awestgaa@ous-hf.no](awestgaa@ous-hf.no)  \n† These authors contributed equally to this work and are joint senior authors.  \nAbstract: Patients with advanced gastrointestinal cancers often receive chemotherapy near the end of life (EoL), raising concerns about overtreatment. The PALLiON trial, a cluster-randomized trial, assessed the impact of a complex intervention on frequency of EoL treatment; the intervention involved palliative care referrals and the use of PROMs. The present secondary analysis evaluated the prognostic value of baseline performance status (PS), albumin (alb), C-reactive protein (CRP), and body mass index (BMI) for overall survival, comparing pancreatic (PAN, n = 189) vs. other gastrointestinal cancer patients (GI, n = 286) . Baseline PS, alb, CRP, mGPS (modiﬁed Glasgow prognostic score), and BMI were analyzed using Cox regression. Adjusted for age, sex, and hospital size, PS 􀀕 2 and alb \u003C 35 g/L predicted shorter survival in both PAN and GI cancers, while CRP > 10 predicted shorter survival only in GI cancers. In PAN, PS 􀀕 2 predicted a 78.4% higher probability of shorter survival, and mGPS 2 predicted a 68.7% higher probability. In GI, mGPS 2 predicted a 70.8% higher probability, whereas PS was not signiﬁcant. BMI did not improve predictive models. PS 􀀕 2 and low albumin are strong predictors of short survival in PAN, whereas increased CRP and low albumin (mGPS 2) are predictors in GI.  \nKeywords: pancreatic adenocarcinoma; gastrointestinal cancer; end-of-life chemotherapy; palliative care  \n1. Introduction  \nPatients with pancreatic (PAN) and other gastrointestinal (GI) cancers often receive systemic treatment near the end of life (EoL), raising concerns about overtreatment. Prognosis varies signiﬁcantly due to factors like tumour biology, patient comorbidities, and treatment responses. In patients with advanced cancer, treatment decisions must balance life extension beneﬁts with therapy risks and burdens to the patients and the family. A nuanced approach is essential to prioritize the patient's quality of life, avoid unnecessary interventions, and minimize hospital visits whenever possible [1] .  \nNorway's public healthcare system provides universal health care for all cancer patients. Despite Norway being frequently ranked among the best public health systems globally [2,3], there is a notable variation at the national level in the timing of cessation of EoL chemotherapy for PAN across Norwegian u","cbCaieqXzbDZQqjq","https://ap.wps.com/l/cbCaieqXzbDZQqjq","pdf",1356301,"English","# Introduction\n## Prognostic tools and biomarkers\n## The PALLiON trial and mGPS rationale","[{\"question\":\"What baseline factors were assessed for prognosis in last-line chemotherapy patients?\",\"answer\":\"Baseline performance status (PS), albumin (alb), C-reactive protein (CRP), and body mass index (BMI) were evaluated for overall survival, alongside the modified Glasgow prognostic score (mGPS).\"},{\"question\":\"How did PS and albumin relate to survival in pancreatic versus other gastrointestinal cancers?\",\"answer\":\"PS ≤2 and albumin \\u003c35 g/L predicted shorter survival in both pancreatic and other gastrointestinal cancers after adjustment for age, sex, and hospital size.\"},{\"question\":\"Did BMI improve prognostic prediction models?\",\"answer\":\"No. BMI did not improve predictive models, whereas PS and albumin (and increased CRP with low albumin for mGPS ≤2 in GI) were more informative.\"}]","Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers—Simple Tools Matter | PDF",1790010394,25]